Front Row Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

Front Row Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-133	Closed	-$3K	–	1062
2018 Q1	$3K	Buy	+133	New	+$2.61K	﹤0.01%	752

Front Row Advisors's IPXL Position: Q2 2018 in Review

Front Row Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 133 shares — an estimated $3K sold.

Front Row Advisors first reported a position in IPXL in Q1 2018 and held it in 1 quarter. The position peaked at $3K in Q1 2018. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Front Row Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Front Row Advisors sold 133 Impax Laboratories, Inc. shares in Q2 2018, an estimated $3K.
Front Row Advisors first reported a position in Impax Laboratories, Inc. in Q1 2018 and held it in 1 quarter.
Front Row Advisors's Impax Laboratories, Inc. position peaked at $3K in Q1 2018.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Front Row Advisors's 13F filing for Q2 2018, filed 31 Jul 2018.